NCT01863953

A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 112 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

This is a safety and efficacy study of fixed-combination bimatoprost and brimonidine compared with LUMIGAN® and ALPHAGAN® in patients with chronic glaucoma or ocular hypertension.

Conditions

• Glaucoma
• Ocular Hypertension

Interventions

Type	Name	Description
DRUG	Fixed-Combination Bimatoprost/Brimonidine	One drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.
DRUG	Bimatoprost Ophthalmic Solution 0.01%	One drop bimatoprost ophthalmic solution 0.01% in each eye in the evening for 6 weeks.
DRUG	Vehicle Ophthalmic Solution	One drop vehicle ophthalmic solution in each eye in the morning daily for 6 weeks.
DRUG	Brimonidine Tartrate Ophthalmic Solution 0.2%	One drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.

Timeline

• Start date: 2013-06-01
• Primary completion: 2013-12-01
• Completion: 2013-12-01
• First posted: 2013-05-29
• Last updated: 2015-01-26
• Results posted: 2015-01-26

Locations

1 site across 1 country: United States